José Luis Sánchez-Menoyo

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis et al. · Brain · 2016 · 416 citations · Full text

Life Sciences, Neurology, Neuroscience +12

Defining reliable disability outcomes in multiple sclerosis

Tomáš Kalinčík, Gary Cutter, Tim Spelman et al. · Brain · 2015 · 243 citations · Full text

Medicine, Neurology, Disability Management +16

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 162 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

Tomáš Kalinčík, Dana Horáková, Tim Spelman et al. · Annals of Neurology · 2014 · 159 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Tomáš Kalinčík, Ali Manouchehrinia, Lukáš Sobíšek et al. · Brain · 2017 · 149 citations · Full text

Public Health, Biostatistics, Clinical Epidemiology +15